1032289-55-6

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(2,5-DIMETHYL-PYRROL-1-YL)-PIPERIDINE is used as a building block for the synthesis of biologically active compounds, contributing to the development of new medications with potential therapeutic effects.
Used in Coordination Chemistry:
In the field of coordination chemistry, 4-(2,5-DIMETHYL-PYRROL-1-YL)-PIPERIDINE is used as a ligand, playing a crucial role in the formation and stabilization of metal complexes.
Used in Pharmaceutical Production:
As an intermediate in the production of pharmaceuticals, 4-(2,5-DIMETHYL-PYRROL-1-YL)-PIPERIDINE aids in the synthesis of various drug molecules, enhancing the efficiency and effectiveness of drug manufacturing processes.
Used in the Synthesis of Heterocyclic Compounds and Natural Products:
4-(2,5-DIMETHYL-PYRROL-1-YL)-PIPERIDINE is utilized as a useful reagent in the synthesis of heterocyclic compounds and natural products, facilitating the creation of complex molecular structures with potential applications in medicine and other fields.

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 110-13-4 2,5-hexanedione 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 1108147-59-6 1-benzyl-4-(2,5-dimethyl-1H-pyrrol-1-yl)piperidine 

Relevant academic research and scientific papers

Convenient strecker reactions of piperidine derivatives with cyclic ketones under aqueous conditions

Strecker reactions convenient for the preparation of piperidinyl acetonitrile compounds under aqueous conditions are described. The use of TsOH·H2O is the key to afford the desired products in good and reproducible yield. Copyright Taylor & Francis Group,

Structure-activity relationship studies of pyrrolone antimalarial agents

Previously reported pyrrolones, such as TDR32570, exhibited potential as antimalarial agents; however, while these compounds have potent antimalarial activity, they suffer from poor aqueous solubility and metabolic instability. Here, further structure-activity relationship studies are described that aimed to solve the developability issues associated with this series of compounds. In particular, further modifications to the lead pyrrolone, involving replacement of a phenyl ring with a piperidine and removal of a potentially metabolically labile ester by a scaffold hop, gave rise to derivatives with improved in vitro antimalarial activities against Plasmodium falciparum K1, a chloroquine- and pyrimethamine-resistant parasite strain, with some derivatives exhibiting good selectivity for parasite over mammalian (L6) cells. Three representative compounds were selected for evaluation in a rodent model of malaria infection, and the best compound showed improved ability to decrease parasitaemia and a slight increase in survival.

Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl] -1H-benzimidazole: Design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent

An endogenous heptadecapeptide, nociceptin/orphanin FQ (N/OFQ), and a G-protein-coupled receptor, N/OFQ peptide (NOP) receptor [or opioid-receptor-like-1 (ORL1) receptor], have been described in terms of its structure, distribution, and pharmacology. Thus